EGFR and colorectal carcinoma: Sym004 also demonstrated efficacy in cetuximab-resistant CRC xenograft models harboring mutations in EGFR, S492R EGFR-mutant DCR7, and G465R EGFR-mutant LIM1215 (Sanchez-Martin et al., 2016).